Inhibikase Therapeutics, Inc.
Develops kinase inhibitors for neurodegenerative and rare cardiopulmonary conditions.
IKT | US
Overview
Corporate Details
- ISIN(s):
- US45719W2052
- LEI:
- Country:
- United States of America
- Address:
- 1000 N. WEST STREET, SUITE 1200, 19801 WILMINGTON
- Website:
- https://www.inhibikase.com/
- Sector:
- Manufacturing
Description
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company that develops small molecule kinase inhibitor therapeutics. The company's primary focus is on creating treatments for neurodegenerative diseases and rare cardiopulmonary conditions. Its pipeline includes IkT-148009, a c-Abl protein kinase inhibitor in clinical development for Parkinson's disease and related disorders. Additionally, the company is advancing its drug candidate IKT-001 for the treatment of pulmonary arterial hypertension (PAH).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inhibikase Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Inhibikase Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inhibikase Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
